Very much positive for Neuren in my mind. Acadia will now look to maximise trofinetide sales, including ROW, but will also likley look to expedite 2591 trials and sales in Rett and Fragile X " with separate sales milestones
and royalties to Neuren identical to trofinetide inside and outside North America". They really have very little else to concentrate on!
Acadia, page-350
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.30 |
Change
0.760(4.59%) |
Mkt cap ! $2.211B | |||
| Open | High | Low | Value | Volume |
| $17.35 | $17.94 | $17.25 | $17.64M | 1.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2533 | $17.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.45 | 1254 | 1 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |